Archives of Virology

, Volume 158, Issue 6, pp 1275–1285

Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus

  • Hae-Mi Nam
  • Kyung-Sil Chae
  • Young-Jo Song
  • Nak-Hyung Lee
  • Joong-Bok Lee
  • Seung-Yong Park
  • Chang-Seon Song
  • Kun-Ho Seo
  • Sang-Moo Kang
  • Min-Chul Kim
  • In-Soo Choi
Original Article

DOI: 10.1007/s00705-013-1612-z

Cite this article as:
Nam, HM., Chae, KS., Song, YJ. et al. Arch Virol (2013) 158: 1275. doi:10.1007/s00705-013-1612-z

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) induces reproductive failure in sows and respiratory problems in pigs of all ages. Live attenuated and inactivated vaccines are used on swine farms to control PRRSV. However, their protective efficacy against field strains of PRRSV remains questionable. New vaccines have been developed to improve the efficacy of these traditional vaccines. In this study, virus-like particles (VLPs) composed of the GP5 and M proteins of PRRSV were developed, and the capacity of the VLPs to elicit antigen-specific immunity was evaluated. Serum antibody titers and production of cytokines were measured in BALB/C mice immunized intramuscularly three times with different doses (0.5, 1.0, 2.0, and 4.0 μg) of the VLP vaccine. A commercial vaccine consisting of inactivated PRRSV and phosphate-buffered saline (PBS) were used as positive and negative controls, respectively. IgG titers to GP5 were significantly higher in all groups of mice vaccinated with the VLPs than in control mice. Neutralizing antibodies were only detected in mice vaccinated with 2.0 and 4.0 μg of the VLPs. Cytokine levels were determined in cell culture supernatants after in vitro stimulation of splenocytes with the VLPs for 3 days. Mice immunized with 4.0 μg of the VLPs produced a significantly higher amount of interferon-gamma (IFN-γ) than mice immunized with the commercial inactivated PRRSV vaccine and PBS. In contrast, immunization with the commercial vaccine induced higher production of IL-4 and IL-10 in mice than mice vaccinated with VLPs. These data together demonstrate the capacity of VLPs to induce both neutralizing antibodies and IFN-γ in immunized mice. The VLP vaccine developed in this study could serve as a platform for the generation of improved VLP vaccines to control PRRSV.

Supplementary material

705_2013_1612_MOESM1_ESM.pptx (82 kb)
Supplementary material 1 (PPTX 82 kb)

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Hae-Mi Nam
    • 1
  • Kyung-Sil Chae
    • 1
  • Young-Jo Song
    • 1
  • Nak-Hyung Lee
    • 1
  • Joong-Bok Lee
    • 1
  • Seung-Yong Park
    • 1
  • Chang-Seon Song
    • 1
  • Kun-Ho Seo
    • 2
  • Sang-Moo Kang
    • 4
  • Min-Chul Kim
    • 5
  • In-Soo Choi
    • 1
    • 3
  1. 1.Department of Infectious Diseases, College of Veterinary MedicineKonkuk UniversitySeoulKorea
  2. 2.Department of Public Health, College of Veterinary MedicineKonkuk UniversitySeoulKorea
  3. 3.Department of Veterinary Science Research Institute, College of Veterinary MedicineKonkuk UniversitySeoulKorea
  4. 4.Department of Biology, Center for Inflammation, Immunity and InfectionGeorgia State UniversityAtlantaUSA
  5. 5.Department of Microbiology and ImmunologyEmory University School of MedicineAtlantaUSA

Personalised recommendations